2nd International Conference on Innovations and Advances in Cancer Research and Treatment

November 06-07,2024 | DoubleTree by Hilton Boston Logan Airport Chelsea Address : 201 Everett Ave, Chelsea, MA 02150, Unit

Towards A Home Companion Diagnostic Test For The Early Detection Of Breast Cancer: The Potential Of The Urine Metabolome

Nur Aimi Aliah Zainurin

Aberystwyth University , UK

Biography :

Miss Aimi Zainurin is a doctoral student (PhD) in Department of Life Sciences, Aberystwyth University, UK, work- ing on breast cancer project under research group of Prof. Mur, Clinical Hub Aberystwyth (https://www.clini- calhubaberystwyth.com/). She graduated with Biochemical-Biotechnology Engineering (Hons) and MSc Bio- technology Engineering in 2017 and 2019 respectively from International Islamic University Malaysia (IIUM). She worked as a scientist trainee in one of the top Asian biopharmaceutical companies and followed as a researcher at National Institute of Health (NIH) in Malaysia before decided to further her study. Her research interests in omics sciences focus on identifying the biomarkers and understanding the underlying relationship between the biomolecules, their molecular processes, and biological pathways to gain insights into disease mechanisms.

Abstract :

Breast cancer is one of the deadliest cancers with 685,000 deaths and 2.26 million cases reported in 2020. Early detection is crucial for better treatment outcome. Mammography is the gold standard screening modality for breast cancer diagnosis but use of a cost-effective companion diagnostic with a high sensitivity and specificity is required to reduce the mortality rates; especially in group perceived to be low risk, e.g., younger women. This study aims to discover the novel biomarkers in liquid biopsies by direct infusion high resolution mass spec- troscopy (DI-MS) to facilitate the development of low-cost and high throughput biomarker assay (or panel of biomarker profiles) that could be exploited such as ELISA. Metabolite pro- filing focused on urine samples from breast cancer (BC; n=9), benign breast disease (BBD; n=31), symptomatic control (SC; n=35) and age-matched healthy control (HC; n=24) groups, using DI-MS. Multivariate statistical analyses used the R-based Metaboanalyst platform. Data mining revealed 185 urinary metabolites that significantly (p